The US Food and Drug Administration has approved the SPOT-Light HER2 CISH genetic test kit which can determine whether patients with breast cancer are good candidates for treatment with the drug Herceptin. The test identifies if a patient has too many copies of the gene for HER2 protein which causes cells to grow and divide too quickly.
Herceptin effectively targets HER2 protein production and helps stop the growth of cancer cells.
GELLER, J. 'Food and Drug Administration approves 4 new medical devices' Journal of Clinical Engineering October/December 2008 vol 33(4) p. 166-68.
FDA Press Release
Subscribe to posts
Wednesday, 24 December 2008
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment